Journal profile · Pharmacology & Pharmacy
Current Signal Transduction Therapy
ISSN 1574-3624 · eISSN 2212-389X · Bentham Science Publishers B.V. · U ARAB EMIRATES · Tri-annual · Founded 2006
Current Signal Transduction Therapy: subscription journal; median 116 days to acceptance (52 articles, last 24 months); community-reported acceptance: easy; 20 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Current Signal Transduction Therapy is published by Bentham Science Publishers B.V.. By OpenAlex counts of its recent articles, its largest topics are Computational Drug Discovery Methods, Protein Kinase Regulation and GTPase Signaling and Cancer Mechanisms and Therapy, together about 21.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders. The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Computational Drug Discovery MethodsComputer Science7.9%
- Protein Kinase Regulation and GTPase SignalingBiochemistry, Genetics and Molecular Biology7.4%
- Cancer Mechanisms and TherapyMedicine6.1%
- PI3K/AKT/mTOR signaling in cancerBiochemistry, Genetics and Molecular Biology5.9%
- Glioma Diagnosis and TreatmentMedicine5.4%
- Cell death mechanisms and regulationBiochemistry, Genetics and Molecular Biology4.5%
- Cytokine Signaling Pathways and InteractionsMedicine4.5%
- Cancer Cells and MetastasisMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology (medical) | Q4 | 211/278 | 24th |
| Endocrinology | Q4 | 117/132 | 11th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 1.2LetPub ·
- SJR 2026-06
- 0.15LetPub ·
- SNIP 2026-06
- 0.14LetPub ·
- h-index
- 15LetPub ·
- h-index
- 27OpenAlex ·
- i10-index
- 79OpenAlex ·
- 2-year mean citedness
- 0.64OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 19LetPub ·
Articles by year OpenAlex count · 614 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 43 | 0 | 140 |
| 2025 | 20 | 0 | 182 |
| 2024 | 24 | 0 | 192 |
| 2023 | 19 | 1 | 191 |
| 2022 | 21 | 0 | 259 |
| 2021 | 19 | 4 | 243 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
116 daysMedian, submission to acceptance · P25–P75 96 days – 137 days
- Acceptance to online
- median 147 days (52 articles)
- Submission to online
- median 291 days
- Sample
- 52 articles with submission and acceptance dates (69 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- U ARAB EMIRATES
- Frequency
- Tri-annual
- Founded
- 2006
- ISSN
- 1574-3624
- Electronic ISSN
- 2212-389X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Signal Transduction Therapy
How long does peer review take at Current Signal Transduction Therapy?
Based on the dates recorded on 52 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 116 days (interquartile range 96–137 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Signal Transduction Therapy?
According to LetPub and DOAJ records, Current Signal Transduction Therapy is indexed in Scopus.
Is Current Signal Transduction Therapy open access, and what is the APC?
Current Signal Transduction Therapy is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .